Compare · LH vs YDES
LH vs YDES
Side-by-side comparison of Labcorp Holdings Inc. (LH) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LH and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH is the larger of the two at $29.95B, about 92.7x YDES ($323.0M).
- Over the past year, LH is up 41.0% and YDES is down 52.0% - LH leads by 93.0 points.
- LH has been more active in the news (14 items in the past 4 weeks vs 1 for YDES).
- LH has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Labcorp Holdings Inc.
- YD Bio Limited
- Price
- $368.96-0.53%
- $4.57-2.56%
- Market cap
- $29.95B
- $323.0M
- 1M return
- +14.11%
- -20.61%
- 1Y return
- +41.04%
- -52.00%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 1
- Recent ratings
- 25
- 0
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest LH
- OTraces Selects Labcorp to Perform Biomarker Testing for Florida Department of Health–Funded Prostate Cancer Study
- EVP, Chief Marketing Officer Amy B. Summy sold $135,992 worth of shares (365 units at $372.58), decreasing direct ownership by 5% to 6,590 units (SEC Form 4)
- Labcorp to Expand Clinical Trial Operations in Brazil with Dedicated Kit Assembly and Future Laboratory Operations through Collaboration with Grupo Fleury
- EVP, Pres of BLS, CMO & CSO Caveney Brian J sold $744,080 worth of shares (2,000 units at $372.04), decreasing direct ownership by 5% to 34,562 units (SEC Form 4)
- EVP and President, Diagnostics Vaughn Bryan T sold $108,232 worth of shares (306 units at $353.70) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 6,845 units (SEC Form 4)
- Labcorp Holdings Inc. upgraded by HSBC Securities with a new price target
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Speak at the UBS Global Healthcare Conference
- Director Parham Richelle P sold $389,395 worth of shares (1,078 units at $361.22), decreasing direct ownership by 32% to 2,288 units (SEC Form 4)
- EVP, CIO & CTO Oyegunwa Akinbolade converted options into 370 shares and covered exercise/tax liability with 118 shares, increasing direct ownership by 5% to 5,316 units (SEC Form 4) to satisfy tax liability
Latest YDES
- YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
- YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
- SEC Form 4 filed by YD Bio Limited
- SEC Form 4 filed by YD Bio Limited
- YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
- CEO Shen Ethan Phd bought $48,895 worth of Ordinary Shares (12,700 units at $3.85), increasing direct ownership by 0.11% to 11,258,331 units (SEC Form 4)
- CEO Shen Ethan Phd bought $12,183 worth of Ordinary Shares (3,100 units at $3.93), increasing direct ownership by 0.03% to 11,245,631 units (SEC Form 4)
- CEO Shen Ethan Phd bought $67,447 worth of Ordinary Shares (18,378 units at $3.67), increasing direct ownership by 0.16% to 11,242,531 units (SEC Form 4)
- YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute